Shockwave therapy shows promising early results for certain types of neuropathy, particularly in improving sensory nerve function and reducing pain. However, it has not yet been included in major clinical guidelines for neuropathy treatment, and the evidence is still building. What exists so far suggests it can meaningfully improve sensory nerve conduction velocity and may help nerves recover, but it works better as a complement to other therapies than as a standalone fix.
What Shockwave Therapy Does to Nerves
Extracorporeal shockwave therapy (ESWT) delivers focused pressure waves through the skin to targeted tissues. For neuropathy, the goal is to stimulate nerve repair at the cellular level. The therapy activates Schwann cells, which are the support cells that wrap around and maintain peripheral nerves. When these cells are activated, they dedifferentiate (essentially reverting to an earlier, more flexible state) and then multiply, creating a better environment for damaged nerves to regrow.
This activation happens through specific signaling pathways inside the cell. Shockwaves trigger a cascade that promotes the production of neurotrophic factors, proteins that encourage nerve survival and growth. The therapy also stimulates new blood vessel formation in treated areas, which improves blood supply to oxygen-starved nerves. On top of that, shockwaves appear to boost production of a compound called thioredoxin-1, which has antioxidant properties and helps suppress cell death in damaged nerve tissue.
What the Clinical Evidence Shows
A systematic review and meta-analysis published in Frontiers in Neurology pooled data from multiple trials and found that shockwave therapy improved sensory nerve conduction velocity both in the short term and at mid-term follow-up. Sensory nerves carry signals like touch, temperature, and pain, so faster conduction means those signals travel more efficiently. The improvement was statistically significant when comparing measurements before and after treatment.
Motor nerve conduction velocity, which governs muscle movement, did not improve significantly. This is an important distinction: if your neuropathy primarily causes numbness, tingling, or burning pain, shockwave therapy may offer more benefit than if your main symptoms involve muscle weakness or loss of coordination.
When shockwave therapy was added to physical therapy, the combination produced larger improvements in sensory nerve conduction than physical therapy alone. This supports the idea that ESWT works best as part of a broader treatment plan rather than a replacement for other approaches.
Neuropathy Types With the Most Evidence
Most of the clinical research has focused on diabetic peripheral neuropathy, which is the most common form. The sensory nerve improvements seen in meta-analyses largely come from studies of diabetic patients. If you have diabetes-related numbness or tingling in your feet and hands, this is where the strongest (though still limited) data exists.
For chemotherapy-induced peripheral neuropathy, which affects up to 65% of cancer patients, the direct evidence for shockwave therapy specifically is thinner. Studies in this population have more broadly examined physiotherapy-based interventions, including therapeutic ultrasound and exercise programs, and found improvements in sensory and motor symptoms, balance, muscle strength, and quality of life. No serious adverse events were reported, and treatment adherence ranged from 70% to 95%. But dedicated large-scale trials testing ESWT for chemotherapy-induced neuropathy are still lacking.
There is also preliminary research on postherpetic neuralgia (nerve pain after shingles) and carpal tunnel syndrome, both of which involve nerve dysfunction. Early results are encouraging, but sample sizes remain small.
What a Typical Treatment Looks Like
A standard course involves three to five sessions spaced about one week apart. Each session typically lasts around 15 minutes. The device is placed against the skin over the affected area, and a coupling gel helps transmit the pressure waves.
During treatment, the energy is gradually increased from a low level up to the maximum intensity you can tolerate. Most people describe the sensation as a rapid tapping or pulsing that ranges from mildly uncomfortable to moderately painful at higher settings. You can ask the provider to adjust the intensity at any point. No anesthesia or numbing is required, and you can walk out and resume normal activities immediately afterward.
How Long Results Last
Long-term follow-up data specific to neuropathy is limited. The best durability data comes from related musculoskeletal conditions treated with radial shockwave therapy. In one retrospective study, pain scores dropped 48% at one month, 68% at three months, and 86% at one year after treatment. The one-year success rate reached 98%, with only an 8% recurrence rate. While these numbers come from plantar fascia patients rather than neuropathy patients specifically, they suggest shockwave therapy’s effects tend to build over time rather than fade quickly, likely because the therapy triggers biological repair processes that continue after sessions end.
For neuropathy, the meta-analysis data showed improvements persisting at mid-term follow-up (typically measured at several months). Whether the benefits hold beyond six months to a year for nerve-related conditions remains an open question.
Side Effects and Safety
Shockwave therapy has a favorable safety profile. In a large systematic review, about 20.7% of patients experienced minor, temporary side effects: mild pain at the treatment site, slight swelling, or small bruise-like spots (petechiae). These were more common with higher-energy settings and resolved on their own.
Several conditions rule out shockwave therapy entirely. You should not receive ESWT if you have a cardiac pacemaker, are pregnant, have an active infection in the treatment area, a blood clotting disorder, a tumor near the treatment site, or severe osteoporosis or fracture in the area being treated.
Cost and Insurance Coverage
Shockwave therapy is generally not covered by insurance plans. At UCHealth, for example, a full treatment package costs around $550, which covers up to six 15-minute sessions. Costs vary by provider and region, but expect to pay somewhere in the range of $100 to $150 per session out of pocket. If you have a Health Savings Account (HSA) or Flexible Spending Account (FSA), those funds can typically be applied toward shockwave therapy.
Where It Stands in Treatment Guidelines
As of 2025, shockwave therapy has not been added to the American Diabetes Association’s Standards of Care or other major clinical guidelines for peripheral neuropathy. The current standard of care still centers on blood sugar management, pain medications, and physical therapy. This doesn’t mean ESWT is ineffective, but it does mean the evidence hasn’t yet reached the threshold that guideline committees require, typically multiple large, high-quality randomized controlled trials with consistent results. For now, shockwave therapy sits in the category of a promising adjunctive treatment with real biological plausibility and encouraging early data, but not yet a first-line recommendation.